Current Atherosclerosis Reports

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	157
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	144
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	115
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes	113
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	99
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	79
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	78
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	67
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	67
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease	66
The Role of the PI3K/Akt/mTOR Pathway in Atherosclerosis: Mechanisms, Therapeutic Potential, and Emerging Targeted Treatments	65
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart	57
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	56
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	51
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	51
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis	43
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	43
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	41
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event	41
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	38
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	38
Inflammation in the Peri-ACS Period: Ready for Prime Time?	37
The Emerging Specialty of Cardio-Rheumatology	36
Percutaneous Coronary Interventions in Women	35
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	35

The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	34
Lipoprotein(a): from Causality to Treatment	32
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease	31
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	31
Myeloid Cells in Abdominal Aortic Aneurysm	30
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?	30
Low LDL-C: Is It all Good News?	29
The Role of Sleep in Cardiovascular Disease	29
Importance of Nutrition Security to CVD Prevention Efforts in the USA	28
Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations: What Clinicians Need to Know?	28
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger	27
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?	27
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion	26
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease	26
Can Clinical Biomarkers Guide Optimal Therapeutic Selection in Type 2 Diabetes Mellitus? A Scoping Review	25
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis	24
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment	24
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis	24
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know	23
Exploring the Role of SPARC in Atherosclerosis: Mechanisms and Potential Implications	23
Transgender Cardiovascular Health: Practical Management for the Clinician	23
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity	22
Transforming Population Health Screening for Atherosclerotic Cardiovascular Disease with AI-Enhanced ECG Analytics: Opportunities and Challenges	22
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?	22
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	22
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference	21
Factors Affecting Circulating Phytosterol Levels: Toward an Integrated Understanding of Atherogenicity and Atheroprotection by Dietary and Circulating Phytosterols	21
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction	20
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?	20
Clinical Management of Dyslipidemia in Infants and Toddlers	19
Is There a Role for Imaging Youth at Risk of Atherosclerosis?	19
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine	19
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference	19
Cardiovascular Disease in the Middle East and North Africa, 1990–2021: Burden, Trends, and Risk Factors	19
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease	19
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know	18
Gene Regulatory Networks in Coronary Artery Disease	18
HIV and Cardiovascular Disease Burden in Young Adults (18–25 years): A Review of Current Evidence	18
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults	18
Cardiovascular Health and Disease in the Pakistani American Population	18
Expanding Clinical Indications for Cardiac CT: A Review of Its Current Utility in American and European Guidelines	18
Natural Sirtuin1 Activators and Atherosclerosis: an Overview	17
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population	17
Targeting the Gut Microbiome to Treat Cardiometabolic Disease	17
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference	17
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men	16
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field	16
High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review	16
Bempedoic Acid: for Whom and When	16
What Causes Premature Coronary Artery Disease?	16

Dietary Management of Atherogenic Dyslipidemia	15
Correlation Between Oral Bacteria and Atherosclerotic Thrombotic Disease: Advances in Animal Model Studies	14
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments	14
Fixed Combination for the Treatment of Dyslipidaemia	14
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms	14
Utility of FFRCT in Patients with Chest Pain	14
The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?	14
Serial Coronary CTA for Monitoring Response to Lipid-Lowering Therapy: A Narrative Review	14
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned	14
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk	14
Apheresis: What Should a Clinician Know?	13
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach	13
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions	13
Circular RNA role in Atherosclerosis Development and Progression	13
Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk	13
Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches	13
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?	13
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention	13
Statins as Modulators of Epithelial to Mesenchymal Transition in Cardiovascular-Kidney-Metabolic Syndrome: a Comprehensive Review of Mechanisms and Therapeutic Implications	12
Cardiovascular Disease Burden among African Migrants	12
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia	12
The TICE Pathway: Mechanisms and Potential Clinical Applications	12
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation	12
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges	12
Can Digital Health Solutions Fill in the Gap for Effective Guideline Implementation in Cardiovascular Disease Prevention: Hope or Hype?	12
HDL as a Treatment Target: Should We Abandon This Idea?	12
Obicetrapib—the Rebirth of CETP Inhibitors?	12
Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering Therapy	12
Statin Use and Hyperglycemia: Do Statins Cause Diabetes?	11
CETP Inhibitors: Should We Continue to Pursue This Pathway?	11
The Atherosclerotic Plaque Microenvironment as a Therapeutic Target	11
Advances, Challenges, and Progress in Cardiac Rehabilitation in Chronic CVD Management	11
How to Handle Elevated Triglycerides: Life after PROMINENT	11
S-Nitrosylation: Mechanistic Links between Nitric Oxide Signaling and Atherosclerosis	11
Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme?	11
Psychological Health and Ischemic Heart Disease in Women: A Review of Current Evidence and Clinical Considerations across the Healthspan	11
Unveiling the Sex-Based Divide: Exploring Sex Differences in Peripheral Artery Disease	11
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment	11
LDL Transcytosis by the Arterial Endothelium—Atherosclerosis by a Thousand Cuts?	10
Gene Editing for the Treatment of Hypercholesterolemia	10
Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?	10
Myocardial Bridge and Atherosclerosis, an Intimal Relationship	10
Update on Sitosterolemia and Atherosclerosis	10
Artificial Intelligence-Enabled Point-of-Care Echocardiography: Bringing Precision Imaging to the Bedside	10
Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence	10
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes	10
Ancestral Variation in Lp(a): Epidemiology, Isoform Diversity, and Testing	10
JAM-A: Adhesion Receptor and Signaling Regulator in Atherosclerosis	10
An Update on Nutrition Guidance for Cardiovascular Health	10
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?	10
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy	10
Mechanisms Behind NAFLD: a System Genetics Perspective	10
Family Meals and Cardiometabolic Risk Factors in Young Children	10
Correction to: Built Environment and Cardiovascular Diseases – Insights from a Global Review	9
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes	9
“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”	9
Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity?	9
Biomarkers Differentiating Plaque Erosion from Stable Plaque	9
Eggs and Cardiovascular Disease Risk: An Update of Recent Evidence	9
Health Literacy is Essential to ASCVD Prevention in Youth	9
Correction to: Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	9
Correction to: Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	9
The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder	9
Transitioning Adolescents and Young Adults with Lipid Disorders to Adult Health Care	9
Incidental Finding of Coronary and Non-Coronary Artery Calcium: What Do Clinicians Need To Know?	8
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)	8
Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes	8
Updates in Small Interfering RNA for the Treatment of Dyslipidemias	8
Invasive Coronary Assessment in Myocardial Ischemia with No Obstructive Coronary Arteries	8
Mechanosensing and Mechanosignal Transduction in Atherosclerosis	8
Familial Combined Hyperlipidemia: Myth or Reality?	8
Effects of the COVID-19 Pandemic on Pediatric and Adolescent ASCVD Risk Factors	8
Inclisiran: How Widely and When Should We Use It?	8
Insight into the Mechanistic role of Colchicine in Atherosclerosis	8
Impact of Sex Differences on Lipids and Statin Utilization	8
Sport as Medicine for Dyslipidemia (and Other Risk Factors)	8
ADAMTS7: a Novel Therapeutic Target in Atherosclerosis	8
Statin Intolerance: an Overview of US and International Guidance	8
Double-Trouble: Atherosclerotic Risk Factors and Congenital Heart Disease	8
The Role of Cardiac PET in Diagnosis and Prognosis of Ischemic Heart Disease: Optimal Modality Across Different Patient Populations	8

Tackling the Cardio-Kidney-Metabolic Burden in Cancer	8
PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?	7
Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus	7
SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?	7
From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD’s Cardiometabolic Risks	7
Built Environment and Cardiovascular Diseases – Insights from a Global Review	7
The Pandemic of Coronary Heart Disease in the Middle East and North Africa: What Clinicians Need to Know	7
Medical Nutrition Therapy Provided by Dietitians is Effective and Saves Healthcare Costs in the Management of Adults with Dyslipidemia	7
Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?	7
Sex-based Differences in Complications Following Percutaneous Coronary Interventions	7
Predictive Modeling and Structure Analysis of Genetic Variants in Familial Hypercholesterolemia: Implications for Diagnosis and Protein Interaction Studies	7
Lp(a): A Rapidly Evolving Therapeutic Landscape	7